Novo Nordisk's stock is experiencing an uptick today following the European Commission's approval of Novo Holdings A/S' acquisition of Catalent, Inc., a global contract development and manufacturing organization. This approval, announced on December 6, 2024, also includes Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings A/S. The strategic acquisition is expected to enhance Novo Nordisk's manufacturing capabilities, potentially leading to increased production efficiency and capacity, which investors view positively.
Novo Nordisk (NVO) shares are currently trading at $111.16, reflecting a 2.15% increase from the previous close of $108.82. The stock opened at $109.93 and has seen a 1.12% rise from the opening price.